EGQ0 Stock Chart & Stats
€0.21
-€0.02(-5.23%)
At close: 4:00 PM EST
€0.21
-€0.02(-5.23%)
Day’s Range― - ―
52-Week Range€0.07 - €0.31
Previous CloseN/A
Volume0.00
Average Volume (3M)33.00
Market Cap
€12.39M
Enterprise Value€67.66M
Total Cash (Recent Filing)€9.35M
Total Debt (Recent Filing)€289.39K
Price to Earnings (P/E)―
Beta-0.26
Next Earnings
Feb 19, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding140,775,450
10 Day Avg. Volume0
30 Day Avg. Volume33
Financial Highlights & Ratios
PEG Ratio1.11
Price to Book (P/B)3.81
Price to Sales (P/S)166.47
P/FCF Ratio-10.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)€1.19M
Bulls Say, Bears Say
Bulls Say
Diagnostic And Research PlatformINOVIQ operates across diagnostic and research applications, giving its biomarker technology several potential routes to commercialisation. A platform serving clinical and research users can support broader adoption and future product expansion if the company converts development work into recurring sales.
Low Financial LeverageVery low leverage reduces balance-sheet risk and avoids the interest burden associated with substantial borrowings. This provides greater financial flexibility than a highly indebted structure, allowing management to direct available resources toward development and commercialisation while limiting refinancing pressure.
Losses Narrowed From Historical ExtremesThe reduction in losses from the FY2022 extreme suggests some progress in controlling the earnings deficit over time. While this has not yet produced sustainable profitability, continued improvement in operating efficiency could gradually reduce the funding burden as the company develops its commercial base.
Bears Say
Sharp Revenue ContractionA revenue decline of this magnitude weakens evidence that current products and services are achieving reliable commercial traction. The smaller revenue base also makes operating performance more volatile and leaves the company with less capacity to absorb development costs or build a path toward self-funded growth.
Persistent Unprofitable OperationsLarge recurring losses indicate that the existing revenue base does not yet support the company’s operating cost structure. Unless commercial scale improves materially or expenses fall, continued deficits can consume shareholder capital and make sustainable profitability dependent on successful product adoption.
Ongoing Cash BurnPersistent negative operating cash flow means INOVIQ is not currently funding operations from internally generated cash. The deterioration in FY2026 increases reliance on its balance sheet or future capital sources, potentially limiting investment flexibility and raising the importance of achieving commercial cash generation.
Inoviq Ltd News
EGQ0 FAQ
What was Inoviq Ltd’s price range in the past 12 months?
Inoviq Ltd lowest stock price was €0.07 and its highest was €0.31 in the past 12 months.
What is Inoviq Ltd’s market cap?
Inoviq Ltd’s market cap is €12.39M.
When is Inoviq Ltd’s upcoming earnings report date?
Inoviq Ltd’s upcoming earnings report date is Feb 19, 2027 which is in 115 days.
How were Inoviq Ltd’s earnings last quarter?
Inoviq Ltd released its earnings results on Sep 16, 2026. The company reported -€0.015 earnings per share for the quarter.
Is Inoviq Ltd overvalued?
According to Wall Street analysts Inoviq Ltd’s price is currently Overvalued.
Does Inoviq Ltd pay dividends?
Inoviq Ltd does not currently pay dividends.
What is Inoviq Ltd’s EPS estimate?
Inoviq Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Inoviq Ltd have?
Inoviq Ltd has 140,775,450 shares outstanding.
What happened to Inoviq Ltd’s price movement after its last earnings report?
Inoviq Ltd reported an EPS of -€0.015 in its last earnings report. Following the earnings report the stock price went up 4.819%.
Which hedge fund is a major shareholder of Inoviq Ltd?
Currently, no hedge funds are holding shares in DE:EGQ0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inoviq Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
DE:EGQ0 Sentiment 92%
Sector Average 67%
Sector Average 67%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.82%
12-Months-Change
Fundamentals
Return on Equity
-36.48%
Trailing 12-Months
Asset Growth
10.81%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Inoviq Ltd
INOVIQ Ltd specializes in the research, development, and commercialization of diagnostic and exosome-based products, aiming to improve the detection and treatment of cancer and other conditions across Australia and the United States. Its current portfolio includes the hTERT test, an immunocytochemistry assay that serves as a supplementary tool for urine cytology in bladder cancer screening, alongside EXO-NET, designed for the capture and isolation of exosomes from liquid biopsy specimens. The company also boasts a robust diagnostic pipeline, featuring blood tests currently under development for various cancers, including ovarian and breast cancer. Originally incorporated in 1983 and formerly known as BARD1 Life Sciences Limited until its rebranding to INOVIQ Ltd in December 2021, the company maintains its headquarters in Notting Hill, Australia.
Technical Analysis
Genetic Technologies
―
BCAL Diagnostics Limited
―
Rhythm Biosciences Ltd.
―
Genetic Signatures Ltd.
―
Imagion Biosystems Ltd.
―